Coherus and Mark Cuban to debut lowest priced Humira biosimilar in USA
US biosimilars developer Coherus BioSciences (Nasdaq: CHRS) saw its share rise 5% to $4.05 pre-market, after it announced it will launch Yusimry (adalimumab-aqvh) next month, with a list price of $995 per carton (2 x 40 mg/0.8 mL autoinjectors), the lowest price announced to date of any Humira (adalimumab) copy offering in the USA.
With AbbVie’s (NYSE: ABBV) Humira currently priced at $6,922 per carton of two autoinjectors, the Yusimry price will represent about an 85% discount from the originator, Coherus noted.
According to Coherus, the price of Humira has increased more than 500% since it was first launched in the USA in 2003 at $13,572 per year. The annual cost of Humira, which is still notching up sales of over $20 billion a year, is now nearly $90,000, and the annual cost of Yusimry will be approximately $13,000, representing a discount of about 85%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze